source
- STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and moreNovartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx BioSTAT · 24d ago↗ source
- The race for an Ebola therapy beginsMale marathoners "hit the wall," mental health in 2026, and more Morning Rounds newsSTAT · 24d ago↗ source
- Opinion: The smart way to regulate the peptide boom“The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.STAT · 24d ago↗ source